KRAS/NRAS Mutation-Associated Transcriptional Dysregulation and NRL, CREM and IL6 Expression in Relation to Clinical Outcomes in Multiple Myeloma
International Journal of Molecular Sciences · 18.11.2026 · 27 (22) · 10336
DOI: 10.3390/ijms272210336 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 18.11.2026. Verfasst von Anna M. Sergeeva und 6 weiteren Autor:innen. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Multiple myeloma (MM) is a biologically heterogeneous plasma cell malignancy with variable responses to induction therapy that are not fully explained by current risk stratification systems. Mutations in RAS family genes (KRAS and NRAS) are prevalent in MM, yet contemporary risk stratification systems do not include them despite their oncogenic potential. Our previous findings showed reduced response depth to bortezomib-containing triplet induction regimens in the presence of RAS mutations. The aim of this study is to identify RAS pathway–related molecular targets and evaluate their relationship with clinical outcomes. Forty-four patients with newly diagnosed MM received bortezomib-based induction therapy (velcade + cyclophosphamide + dexamethasone, VCD or velcade + doxorubicin + dexamethasone, PAD/VCD). Bone marrow CD138+ plasma cells were isolated for transcriptome analysis. KRAS and NRAS gene mutations were identified by Sanger sequencing, and RNA sequencing was performed on the Illumina HiSeq 3000 platform. Gene expression was analyzed using Salmon and DESeq2. The clinical endpoints were depth of response, event-free survival (EFS), and overall survival (OS). Of the 66 candidate RAS-pathway related genes examined, five—CREM, NRL, IL6, MMP14 and MEF2B—showed significantly higher expression in samples with KRAS and NRAS gene mutations (t-test, p < 0.05). Lower NRL gene expression was associated with achieving CR + VGPR (HR 10.99, 95% CI: 1.26–534.66, p = 0.01). Elevated IL6 gene expression correlated with poorer OS (HR 3.18; p = 0.05), while increased CREM gene expression was associated with shorter EFS (HR 2.62; p = 0.01). The identified association between gene expression and survival was validated using publicly available external datasets (CREM: HR 2.43, 95% CI: 1.15–5.17, p = 0.017; IL6: HR 1.8, 95% CI: 1.41–2.3, p = 0.0000014). Increased expression of NRL, CREM, and IL6 genes in bone marrow plasma cells before treatment in MM patients was associated with adverse clinical outcomes and may reflect the molecular mechanisms underlying the negative effects of KRAS and NRAS gene mutations.
Zitieren
APA
Sergeeva, A. M., Sidorova, Y. V., Chabaeva, Y. A., Kulikov, S. M., Mendeleeva, L. P., Solovev, M. V., & Sudarikov, A. B. (2026). KRAS/NRAS Mutation-Associated Transcriptional Dysregulation and NRL, CREM and IL6 Expression in Relation to Clinical Outcomes in Multiple Myeloma. International Journal of Molecular Sciences, 27(22), 10336. https://doi.org/10.3390/ijms272210336
Vancouver
Sergeeva AM, Sidorova YV, Chabaeva YA, Kulikov SM, Mendeleeva LP, Solovev MV, et al. KRAS/NRAS Mutation-Associated Transcriptional Dysregulation and NRL, CREM and IL6 Expression in Relation to Clinical Outcomes in Multiple Myeloma. International Journal of Molecular Sciences. 2026;27(22):10336. doi:10.3390/ijms272210336
BibTeX
@article{Sergeeva2026,
author = {Sergeeva, Anna M. and Sidorova, Yulia V. and Chabaeva, Yulia A. and Kulikov, Sergey M. and Mendeleeva, Larisa P. and Solovev, Maksim V. and Sudarikov, Andrey B.},
title = {KRAS/NRAS Mutation-Associated Transcriptional Dysregulation and NRL, CREM and IL6 Expression in Relation to Clinical Outcomes in Multiple Myeloma},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {22},
pages = {10336},
doi = {10.3390/ijms272210336}
}
EUVIMED